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OBJECTIVES: In chronic diseases, health-related quality of life (HRQoL), a key 
health outcome measure, varies not just between- but also within-individual 
patients over time due to acute changes in clinical or environmental 
circumstances. Cross-sectional assessments of HRQoL consider only between-
patient differences and do not reflect within-patient changes, which require 
multiple assessments over time. This study aims to disaggregate the between- 
and within-individual factors influencing HRQoL over time in persons with 
hemophilia A. METHODS: In a two-year observational prospective study of 
health care utilization and burden of illness in US hemophilia A patients (HUGS 
Va), the SF-12 (adults) and PedsQL (children aged <18 years) was used to assess 
HRQoL at baseline, 6, 12, 18 and 24 months. Information was also collected about 
disease severity, sociodemographic variables, annual bleeding and emergency 
room visits frequencies and missed days from work/school. RESULTS: Only small 
variations in HRQoL were observed over time in the entire study population of 
157 adults and 164 children, of which 64.6% have severe disease. At baseline, 6, 
12, 18 and 24 months, adult mean mental component scores were 50.9±10.1, 
49.8±9.7, 50.2±10.2, 49.5±10.6 and 50.4±9.5 respectively, while mean physical 
component scores were 43.4±10.7, 43.3±10.8, 50.2±10.2, 49.5±10.6 and 50.4±9.5 
respectively. Among children, mean psychosocial functioning scores at each 
follow-up were 84.1±15.3, 83.3±13.3, 80.3±15.6, 83.5±16.0 and 82.9±13.2 
respectively, while mean physical functioning scores were 89.5±15.2, 85.5±17.8, 
82.7±22.3, 85.7±18.0 and 84.7±17.3 respectively. After plotting the HRQoL scores of 
individuals over time, however, greater variations in the magnitude and pattern 
of fluctuation can be observed, reflecting acute within-patient changes. 
CONCLUSIONS: HRQoL fluctuates over time on the individual level, but not at 
the study population level as aggregation of scores to the mean masks individual 
variation. In order to identify factors influencing changes in HRQoL across time, 
multivariate multilevel modelling will be employed to disaggregate between- and 
within-individual differences in HRQoL.  
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OBJECTIVES: To analyse the impact of systemic lupus erythematosus (SLE) on 
Portuguese patients’ quality of life. METHODS: Study conducted in one 
Portuguese hospital with a Auto-immune Disease Unit, sample size were 116 
patients with SLE. All patients fulfilled the American College of Rheumatology 
(ACR) 1997 revised criteria for the classification of SLE and the date at which the 
fourth SLE classification criterion was observed was recorded as the date of 
diagnosis. Patients were grouped into 3 distinct phenotypes namely neuro-
psychiatric (NPSLE), nephritis and non-NPSLE non-nephritis sub-groups. Quality 
of life measured through SF-36 and EQ-5D. Questionnaires were sent by mail and 
participation was voluntary and confidential. RESULTS: Sixty eight per cent valid 
answers were received (n=79). Respondents were predominantly female (89%) 
with average age 45 years. In these, the average length of disease was 12.3 (±8.7) 
years. Average ACR criteria was 5.1 (±1.26) Quality of life measured through EQ-
5D was 0.61 (±0,32) with a large majority of answers between 0,5 and 1,0. The 
average value for SF-36 mental component was 65 and the physical component 
was 66. CONCLUSIONS: Age was negatively correlated at a significant level with 
results obtained for EQ-5D and the physical component of SF-36. Disease 
duration was also negatively correlated at a significant level with the physical 
component of SF-36. Correlation between QoL instruments was found to be in 
accordance with studies in other countries. QoL measured through SF-36 was 
consistently lower than the Portuguese norm. Results of QoL in Portuguese 
patients with SLE found to be comparable to the scarce available evidence in 
other countries. For both instruments Portuguese patients with SLE reported 
worst HRQoL than Portuguese patients with psoriasis.  
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OBJECTIVES: To characterize physician practice patterns and their approaches 
towards assessment and management of SLE patients in usual practice settings 
in the United States. METHODS: Actively practicing rheumatologists with >= 3 
years of treating SLE were recruited from a panel of > 4,000 rheumatologists in 
the U.S. Physicians completed an online survey covering SLE practice patterns, 
viewpoints and patient communication approaches. Descriptive analyses were 
conducted on the overall sample; subgroups were compared using chi-square 
and t-tests, as appropriate. RESULTS: Between February and April 2012, 304 
physicians from 42 states completed the survey [68% male; mean age: 49; 69% 
community/non-academic; 69% Caucasian)]. Physicians treated SLE patients for a 
mean of 16 years. Mean(SD) time spent by physicians with patients was 52(15) 
minutes at initial visit and 22(7) minutes at follow-up visits. Overall distribution 
of SLE disease severity was 46% mild, 37% moderate, and 17% severe. 73% of 
patients had adequately controlled SLE; and 20% were on moderate to high dose 
of steroids. While 64% of physicians reported involving patients in treatment 
decisions ‘often/very often’, physicians were evenly divided (52% vs. 48%) in 
whether doing so does or does not ‘improve outcomes a lot’. A greater proportion 
of physicians in the former group believed that (a) patient knowledge of clinical 
tests helped improve adherence (51% vs. 32%; p=0.001); b) SLE has a very high 
impact on patient quality of life (27% vs. 17%; p=0.002); c) had greater satisfaction 
with patient interactions (8 vs. 8.4; scale 0-10; p=0.007); and reported setting 
goals with their patients (78% vs. 68%; p=0.05). CONCLUSIONS: Approximately 
half of surveyed physicians believe that involving patients in treatment plans is 
important to attaining favorable outcomes. This belief corresponds to a greater 
appreciation of doctor-patient interactions. Its impact on SLE outcomes and 
factors influencing this belief warrant further research.  
 
PSY71  
APPROACHES TO PAIN MANAGEMENT AMONG OLDER AND YOUNGER ADULTS 
EXPERIENCING MODERATE TO SEVERE PAIN IN A NATIONAL HEALTH SURVEY: 
TOO MUCH OR NOT ENOUGH?  
Vo L1, Annunziata K2, Lapane K3 
1Janssen Scientific Affairs, Raritan, NJ, USA, 2Kantar Health, New York, NY, USA, 3University of 
Massachusetts Medical School, Worcester, MA, USA  
OBJECTIVES: To describe pain management among older adults reporting 
moderate to severe pain and to evaluate the extent to which polypharmacy in 
pain management is associated with greater medication side effects. METHODS: 
The 2011 US National Health and Wellness Survey was used. Participants 
completed a self-administered, internet-based questionnaire, reported pain 
medications (e.g. specific medication, duration of use, days used in past month) 
grouped by number of prescriptions used (0, 1, ≥ 2) and the World Health 
Organization Pain Ladder guidelines. Participants were at least 65 years of age. 
Analyses were appropriately weighted for the complex survey design. RESULTS: 
Of the 16,500 participants ≥65 years of age, 35.9% reported pain in the past 12 
months, with 66% reporting moderate/severe pain. The most common sources of 
pain were: arthritis pain (66.1%), back problems (58.5%), and joint pain (55.3%). 
Daily pain was reported in 60%. Among older adults experiencing 
moderate/severe pain, 50% received no prescription pain medication, 32% 
received one prescription, and 18% received ≥ 2 prescriptions for pain. Relative to 
one prescription, those reporting ≥ 2 prescriptions received stronger analgesics 
(WHO level 3: 28.3% vs. 8.2% for ≥ 2 vs. 1; WHO Level 2: 55.0% vs. 45.2% for ≥ 2 vs. 
1). Use of adjuvants to pain medications were more common in those with ≥ 2 
relative to 1 pain medication. Compared to participants on 1 prescription pain 
medication reporting at least one side effect (n=194), participants on ≥ 2 pain 
medications reporting at least one side effect (n=197) were significantly more 
likely to report bloating (11.0% vs. 6.8%), nausea (16.5% vs. 5.1%), trouble thinking 
clearly (19.0% vs. 6.7%), and sleepiness (47.5% vs. 25.6%). CONCLUSIONS: 
Moderate/severe pain is common among older adults, and for most, occurs daily. 
Pain management appears to be suboptimal and may include polypharmacy in 
pain management as well as under-treatment of pain.  
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OBJECTIVES: Within the EU, pharmaceutical products in development may 
apply for an orphan product designation if the product can demonstrate 
potential value in a rare disease indication. Not all products used in rare diseases 
apply for or receive such a designation. The research question posed was 
whether gaining an orphan drug designation in the EU is indicative of a rare 
disease product achieving greater market access success. METHODS: Products 
receiving an EU Marketing Authorisation (MA) between 2009-2011 with an 
orphan designation were compared with those that were approved for at least 
one indication of use in a rare disease. Indicative markers of market access 
success were reviewed, including outputs of product evaluation 
recommendations from the Scottish Medicines Consortium and HAS in France. 
Additionally, 16 payers in 4 European countries were interviewed for qualitative 
insights on how an orphan designation would impact on their evaluation of 
price. RESULTS: Fourteen (14) products with orphan-product designation 
received an EU MA during 2009-2011. Twenty (20) products without orphan-
designation but with at least one indication for a rare disease received an EU MA 
during 2009-2011. Forty two (42)% of the orphan designated products gaining an 
EU MA received a recommendation for use in Scotland, with 67% of non-orphan 
designated products indicated for a rare disease receiving a recommendation for 
use. Ninety two (92)% of the orphan designated products were included on the 
reimbursement list in France, with 89% of non-orphan designated products 
included on the reimbursement list. Payers indicated that orphan drug status is 
methodologically difficult to consider in relation to price, but it may have other 
relevant market access benefits. CONCLUSIONS: For products with an MA for 
treating rare diseases, the analysis performed concluded that products receiving 
an EU orphan drug designation did not demonstrate greater market access 
success in the selected EU countries using the applied criteria.  
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OBJECTIVES: In the European Union (EU), rare diseases are defined as life-
threatening or chronically debilitating diseases with prevalence lower than five 
